P. Sertić

Cardiac safety of pembrolizumab-based neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: real-world experience from a single centre

The findings are consistent with limited real-world data, showing a 10–12% incidence of cardiovascular symptoms during chemo-immunotherapy and myocarditis rates comparable to clinical trials, which is consistent with limited real-world data.